Louis Garguilo

ARTICLES BY LOUIS

  • 2/6/2025

    Regulatory-CMC is the denominator through the career of Sai Prathyusha Bhamidipati, currently at Moderna. Regulatory-CMC focuses on ensuring compliance with regulations regarding the production and quality control of your pharmaceutical products. Bhamidipati explains the importance for the practice of which when dealing with CDMOs.

  • 2/3/2025

    Professionals in our development and manufacturing outsourcing ecosystem are worried about inadequate training – in-house at their biotechs, and at their CDMOs. A main concern is a lack of sufficiently trained personnel to perform the various technology transfers to keep our industry running efficiently.

  • 1/29/2025

    CDMOs seem determined to do two things more strategically and with a greater focus: build on what they do best (instead of spreading across services); and differentiate themselves by a devotion to customer service. Part two from JPM25.

  • 1/28/2025

    The JP Morgan Healthcare conference has never been a venue for directed discussion on outsourcing. That’s not to say such discussions aren’t held. This year, Kurt Nielsen co-hosted an evening devoted to the topic. Nielsen, a veteran outsourcing-industry executive, shares his initial thoughts on the vibe this year.

  • 1/27/2025

    As the biotech industry continues to evolve, a growing gap in workforce readiness has emerged, driven by insufficient training for both new graduates and experienced professionals transitioning to advanced bioprocessing. Biotech Academy in Rome's Leonardo Sibilio addresses this challenge.

  • 1/20/2025

    Agentic AI is the next artificial-intelligence iteration for the biopharma industry. It propels prediction to autonomous decision-making. It can usher in transformative efficiencies to CDMOs. If you've day-dreamed of more effective external-support, this may be a ticket to that destination.

  • 1/15/2025

    The biopharma industry has generative artificial intelligence (AI) in its employ. After a long wait, we’ve adopted it rather suddenly. Just in time for a new kid in town. Next to ride in is Agentic AI. It will more robustly revolutionize our drug development and manufacturing. A preview of what's to come.

  • 1/13/2025

    You’ve got to give Towards Healthcare credit. They've the fortitude to publish a 10-year projection of how much development and manufacturing outsourcing will add up to globally. Interestingly, personalized medicine may play an outsized role in that growth. Chief Editor Louis Garguilo takes a deeper dive into the Pharmaceutical CDMO Market Companies, Advantages and Segmental Analysis.

  • 1/6/2025

    Chief Editor Louis Garguilo doesn't recall a time of more collective concern over development and manufacturing outsourcing than exhibited during last year's news of Novo Holdings’ purchase of Catalent, and the sale of certain Catalent facilities to Novo Nordisk. That angst was aggravated by the simultaneous drama known as the BIOSECURE Act. Will we have a calmer 2025?

  • 1/2/2025

    Brace for a potentially turbulent 2025. That’s the collective message members of the Outsourced Pharma Editorial Advisory Board provided Chief Editor Louis Garguilo for his first editorial of 2025. They reveal a landscape where geopolitical tensions, regulatory evolutions, and emerging technologies will affect how you develop and manufacture drugs.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.